Orphazyme slumps as FDA issues CRL on lead candidate
F-1
Orphazyme: Update #14 on the AIDNPC Clinical Programme - NPUK
Orphazyme
ARIMOCLOMOL | New Drug Approvals
Orphazyme A/S annonce des changements de direction -Le 23 mai 2022 à 08:52 | Zonebourse
ORPHA 0.8209 +0.02 +2.50% : Orphazyme A/S - MSN Money
Orphazyme A/S : Shareholders Board Members Managers and Company Profile | DK0060910917 | MarketScreener
/cloudfront-us-east-2.images.arcpublishing.com/reuters/67HLJG772NJRXEZ6IOEMA7OK4U.jpg "Danish 'meme stock' Orphazyme plunges after drug setback | Reuters")
Danish 'meme stock' Orphazyme plunges after drug setback | Reuters
Zevra Therapeutics – NNPDF
New drug shows promise against muscle wasting disease | UCL News - UCL – University College London
Drug development: Through the barrier | Nature
ARIMOCLOMOL
Orphazyme raises €80m in oversubscribed IPO - European Biotechnology
a public limited liability company incorporated in Denmark under registration (CVR) no. 32266355) This listing prospectus (the
Orphazyme Completes €20M Series B Financing - FinSMEs
Orphazyme
Orphazyme: Update #11 on the AIDNPC Clinical Programme - NPUK
Articles about Orphazyme
PDF) Lysosomal Storage Diseases and the Heat Shock Response: Convergences and Therapeutic Opportunities.
Cathrine FOG | Senior Scientist | PhD | Orphazyme ApS, Copenhagen | Research profile
Advancing treatment in neurodegenerative rare diseases
UM and Orphazyme Announce Successful Phase II Trial of Arimoclomol in ALS Patients | ALS Center
ARIMOCLOMOL MALEATE
Patents Related to the Cell Biology of the Lysosomal Organelle | Download Table
Articles about Orphazyme | page 3
